{
    "clinical_study": {
        "@rank": "137840", 
        "arm_group": [
            {
                "arm_group_label": "Intervention: Aspirin", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants will undergo aspirin desensitization over a 2-day period with increasing doses of aspirin (60, 125, 325 and 625 mg). Thereafter,they will be followed with 625 mg aspirin bid."
            }, 
            {
                "arm_group_label": "Control: placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants will receive placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effect of aspirin desensitization on symptoms\n      and immunologic profile of patients with aspirin-exacerbated respiratory diseases (AERD)."
        }, 
        "brief_title": "The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma, Aspirin-Induced", 
        "condition_browse": {
            "mesh_term": [
                "Asthma", 
                "Respiration Disorders", 
                "Respiratory Tract Diseases", 
                "Asthma, Aspirin-Induced"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with clinical diagnose of aspirin-exacerbated respiratory disease\n\n          -  History of physician diagnosed asthma.\n\n          -  History of physiacian diagnosed chronic rhinosinositis with nasal polyps.\n\n          -  Positive reaction to aspirin challenge test.\n\n          -  Stable asthma (post-bronchodilator FEV1 of 70% or better, no increase in   baseline\n             dose of oral glucocorticoids for at least 3 months, and no history of hospitalization\n             or emergency room visits for asthma for at least the prior 6 months).\n\n        Exclusion Criteria:\n\n          -  Being smoker\n\n          -  pregnancy\n\n          -  Current breastfeeding\n\n          -  History of bleeding diathesis\n\n          -  History of transient ischemic attack or stroke, or diabetes.\n\n          -  History of abnormal hepatic function\n\n          -  Uncontrolled hypertension or use of beta blocker medication.\n\n          -  History of gastrointestinal ulcers or gastrointestinal bleeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01867281", 
            "org_study_id": "92-01-119-20728"
        }, 
        "intervention": {
            "arm_group_label": "Intervention: Aspirin", 
            "intervention_name": "aspirin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Aspirin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "aspirin", 
            "asthma", 
            "Aspirin desensitization", 
            "Aspirin induced asthma", 
            "Immune System Diseases", 
            "Respiratory Hypersensitivity"
        ], 
        "lastchanged_date": "August 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Department of Allergy and Immunology, Rasool-e-Akram Hospital, Tehran University of Medical Sciences"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases", 
        "overall_official": [
            {
                "affiliation": "Department of Allergy and Immunology, Rasool-e-Akram Hospital, Tehran University of Medical Sciences.", 
                "last_name": "Hossein Esmaeilzadeh, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Department of Allergy and Immunology, Rasool-e-Akram Hospital, Tehran University of Medical Sciences.", 
                "last_name": "Mohammad Nabavi, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Molecular Immunology Research Center, Tehran University of Medical Sciences.", 
                "last_name": "Zahra Aryan, MD, MPH, student", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Iran: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "At baseline and 6 months after treatment, all participants will complete the SNOT-22 questionnaire. SNOT-22 is a validated disease specific questionnaire that assesses the health related quality of life patients.", 
                "measure": "Change in SNOT-22 scores from Baseline", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "At baseline and 6 months after treatment, serum level of IL-10 will be investigated for all participants.", 
                "measure": "change in serum concentration of IL-10", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "At baseline and 6 months after treatment, serum level of TGF-beta will be investigated for all participants", 
                "measure": "change in concentration of serum TGF-beta", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "At baseline and 6 months after treatment, serum level of IFN-gamma will be investigated for all participants.", 
                "measure": "change in concentration of serum IFN-gamma", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "reference": [
            {
                "PMID": "20728206", 
                "citation": "Katial RK, Strand M, Prasertsuntarasai T, Leung R, Zheng W, Alam R. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol. 2010 Oct;126(4):738-44. doi: 10.1016/j.jaci.2010.06.036. Epub 2010 Aug 21."
            }, 
            {
                "PMID": "20920763", 
                "citation": "White AA, Stevenson DD. Does suppression of IL-4 synthesis by aspirin explain the therapeutic benefit of aspirin desensitization treatment? J Allergy Clin Immunol. 2010 Oct;126(4):745-6. doi: 10.1016/j.jaci.2010.08.037."
            }, 
            {
                "PMID": "18699939", 
                "citation": "Rozsasi A, Polzehl D, Deutschle T, Smith E, Wiesmiller K, Riechelmann H, Keck T. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy. 2008 Sep;63(9):1228-34."
            }, 
            {
                "PMID": "18313127", 
                "citation": "Menzies D, Nair A, Meldrum KT, Hopkinson P, Lipworth BJ. Effect of aspirin on airway inflammation and pulmonary function in patients with persistent asthma. J Allergy Clin Immunol. 2008 May;121(5):1184-1189.e4. doi: 10.1016/j.jaci.2008.01.009. Epub 2008 Mar 4."
            }, 
            {
                "PMID": "14610494", 
                "citation": "Swierczynska M, Nizankowska-Mogilnicka E, Zarychta J, Gielicz A, Szczeklik A. Nasal versus bronchial and nasal response to oral aspirin challenge: Clinical and biochemical differences between patients with aspirin-induced asthma/rhinitis. J Allergy Clin Immunol. 2003 Nov;112(5):995-1001."
            }, 
            {
                "PMID": "22643934", 
                "citation": "Vaidyanathan S, Williamson PA, Lipworth BJ. Is a positive nasal lysine-aspirin challenge test associated with a more severe phenotype of chronic rhinosinusitis and asthma? Am J Rhinol Allergy. 2012 May-Jun;26(3):e89-93. doi: 10.2500/ajra.2012.26.3767."
            }, 
            {
                "PMID": "22627848", 
                "citation": "Higashi N, Taniguchi M, Mita H, Yamaguchi H, Ono E, Akiyama K. Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites. Allergol Int. 2012 Sep;61(3):393-403. doi: 10.2332/allergolint.11-RA-0403. Epub 2012 May 25. Review."
            }, 
            {
                "PMID": "22525387", 
                "citation": "Chang JE, White A, Simon RA, Stevenson DD. Aspirin-exacerbated respiratory disease: burden of disease. Allergy Asthma Proc. 2012 Mar-Apr;33(2):117-21. doi: 10.2500/aap.2012.33.3541. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01867281"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "For all participants, Lund Mackay will be scored by investigators.", 
                "measure": "Lund Mackay score", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Number of asthma attacks will be recorded for all participants over a 6-month follow up.", 
                "measure": "Asthma attacks", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Medication needs to relief respiratory symptoms will be recorded for all participants over a 6-month period.", 
                "measure": "medication needs", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "FEV1 for all patients will be assessed using spirometery", 
                "measure": "FEV1", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Tehran University of Medical Sciences", 
        "sponsors": {
            "collaborator": {
                "agency": "Rassoul Akram Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Tehran University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}